Loading organizations...

AI medical imaging solutions provider assisting radiologists in detecting fractures, pathologies, and cancers across X-ray, CT, and MRI.
Based in Paris, France, Gleamer develops AI-powered medical imaging software that assists radiologists in detecting fractures, pathologies, and cancers across X-ray, CT, MRI, and mammography scans. The company operates on a cloud-based software-as-a-service business model, reaching €20 million in annual recurring revenue by December 2024 and securing over 700 customer contracts across 44 countries. Its clinical tools, which include BoneView and ChestView, are designed to reduce diagnostic errors by an estimated 30 percent and accelerate image interpretation times by up to 40 percent. Backed by investors such as Elaia and supported by the France 2030 program, the 130-employee medical enterprise was acquired by RadNet for €230 million to serve as the European AI hub for its DeepHealth division. Gleamer was founded in 2017 by Christian Allouche, Dr. Alexis Ducarouge, and Dr. Nor-eddine Regnard.
Gleamer has raised $45.2M across 4 funding rounds.
Gleamer has raised $45.2M in total across 4 funding rounds.
Gleamer is a Paris-based medical technology company founded in 2017 that develops AI-powered solutions for radiology, primarily through its Gleamer Copilot® platform. This unified AI suite assists radiologists in analyzing medical images across modalities like X-rays, CT scans, mammography, and expanding into MRI, detecting abnormalities such as fractures and lesions to boost diagnostic accuracy, speed up workflows, and prioritize urgent cases[1][2][3][5]. Deployed in over 2,500 clinical sites across 45+ countries, it processes 35-45 million exams annually, serving public and private institutions to reduce healthcare costs, standardize care in underserved areas, and improve patient outcomes[1][5]. With $38M+ in funding, strong clinical validation (30+ publications, 80 studies), and partnerships like Google Cloud and Konica Minolta, Gleamer shows robust growth momentum via geographic expansion and product diversification[1][6].
Gleamer emerged in 2017 in France from a team of medical doctors, engineers, and data scientists who recognized AI's potential to address radiology's growing demands amid radiologist shortages[1][3][4]. Christian Allouche serves as CEO, with Alexis Ducarouge as CTO, driving the vision to make high-quality diagnostics accessible, especially in medical deserts[1][3]. The idea stemmed from deep learning algorithms trained on vast image datasets to spot subtle abnormalities humans might miss, quickly gaining traction with certified products for standard radiology and rapid adoption in Europe and the US[1][2]. Pivotal moments include early deployment in 2,500+ institutions and recent acquisitions of Pixyl and Caerus Medical in 2024 to enter MRI, alongside $29.5M in recent funding[1][6].
Gleamer stands out in the crowded radiology AI market through these key strengths:
Gleamer rides the AI-in-healthcare wave, capitalizing on radiology's acute challenges: global radiologist shortages, rising imaging volumes, and demands for precision in underserved regions[1]. Timing aligns with regulatory approvals (FDA-cleared tools) and post-pandemic workflow pressures, amplified by foundation models enabling multi-modality analysis amid a market projected for rapid AI adoption[1][5]. Favorable forces include falling AI compute costs, vast unlabeled imaging data for training, and payer incentives for cost-saving diagnostics. Gleamer influences the ecosystem by standardizing care quality, fostering AI trust via evidence (publications, adoptions), and enabling "medical deserts" access, positioning it as a leader in equitable, scalable radiology AI[1][3].
Gleamer is poised for accelerated growth by completing its modality suite (MRI imminent post-acquisitions) and deepening US/Europe penetration, potentially doubling exam volumes via more partnerships and foundation model upgrades[1][5][6]. Trends like multimodal AI integration, real-world evidence databases, and regulatory harmonization will propel it, while competition from players like Subtle Medical tests execution. Its influence may evolve from pioneer to platform standard, empowering global radiology equity and tying back to its core mission: AI that makes elite diagnostics ubiquitous for faster, fairer patient care[1][3].
Gleamer has raised $45.2M in total across 4 funding rounds.
Gleamer's investors include Heal Capital, Supernova Invest, Cipio Partners, XAnge, Michael Benabou.
Gleamer has raised $45.2M across 4 funding rounds. Most recently, it raised $5.2M Other Equity in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 5, 2024 | $5.2M Other Equity | ||
| Jun 1, 2023 | $29.0M Series B | Heal Capital, Supernova Invest | Cipio Partners, XAnge, Michael Benabou |
| Sep 1, 2020 | $9.0M Series A | Cipio Partners, XAnge, Michael Benabou | |
| Jul 1, 2018 | $2.0M Seed | Cipio Partners, XAnge, Michael Benabou |